Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
Rev Gaucha Enferm ; 45: e20230141, 2024.
Article in English, Portuguese | MEDLINE | ID: mdl-39166602

ABSTRACT

OBJECTIVE: To understand the meanings attributed to pregnancy in the context of Lupus and antiphospholipid syndrome by women and healthcare professionals. METHOD: Qualitative research, using Symbolic Interactionism as a theoretical framework and Grounded Theory, a constructivist perspective. Data were collected between January and August 2022, through online interviews with 27 women with Lupus located on the social network Facebook and in-person or remote interviews with 12 healthcare professionals. RESULTS: The theoretical model constructed has two categories: "Equal conditions, distinct experiences: experiencing the gestational process" shows that obstetric complications and lack of connection with healthcare professionals trigger negative meanings to the experience; and "Therapeutic management interfering in the attribution of meanings to the experience", demonstrates that the way women interact with healthcare professionals and how they manage treatment favors a positive reframing. FINAL CONSIDERATIONS: The meanings attributed to pregnancy are elaborated and modified according to the interpretation of previous and current experiences, healthcare trajectory and interactions with healthcare professionals. Previous guidance, planning, bonding and trust in healthcare professionals enable positive meanings, while obstetric complications, unqualified assistance and lack of bonding with professionals provide negative meanings.


Subject(s)
Antiphospholipid Syndrome , Grounded Theory , Lupus Erythematosus, Systemic , Pregnancy Complications , Qualitative Research , Humans , Female , Pregnancy , Antiphospholipid Syndrome/psychology , Lupus Erythematosus, Systemic/psychology , Adult , Pregnancy Complications/psychology , Professional-Patient Relations , Young Adult , Attitude of Health Personnel , Health Personnel/psychology
2.
Lupus ; 33(10): 1043-1058, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39045728

ABSTRACT

OBJECTIVE: Substantial morbidity and mortality affect those with antiphospholipid antibodies (aPLs) and antiphospholipid syndrome (APS), yet patient experiences remain poorly understood. This research investigated patient experiences of aPL/APS diagnosis; effects on daily life; and healthcare and treatment. METHODS: Patients aged ≥18 years with APS per the Revised Sapporo criteria or with ≥1 positive aPL on ≥2 occasions were recruited from a Canadian multidisciplinary APS clinic to participate in semi-structured in-depth interviews. Interviews were conducted virtually and transcribed verbatim for subsequent thematic analysis. RESULTS: Twenty-one patients with aPLs/APS participated; 95.2% were female, mean (SD) age was 45.6 (15.0) years. Most (71.4%) had APS, and 71.4% had aPLs/APS with SLE. Results are presented around patient experiences of aPL/APS diagnosis, effects on daily life, and healthcare and treatment. Participants described medical complications/physical symptoms and the healthcare, lifestyle, and emotional impacts experienced around the time of aPLs/APS diagnosis. In addition to the physical and psychosocial impacts of living with aPLs/APS, patients reported modified leisure activities, altered employment trajectories, and positive and negative impacts on relationships. Impacts on family planning were also a critical component of the aPL/APS lived experience; participants shared experiences of miscarriage, other pregnancy complications, and medication-related challenges (e.g., with low-molecular-weight heparin injections). Challenging aspects of aPL/APS healthcare and treatment were also discussed, particularly related to the lifestyle, physical, and emotional burden of medication use. Although a lack of resources was described, participants expressed trust in healthcare providers when making management decisions or when seeking information. Suggestions for resources included the need for additional medication-related information, examples to help contextualize management behaviours, and additional information for those with aPLs/APS without SLE. CONCLUSION: Patients highlighted how the diverse manifestations of aPLs/APS, accentuated by management-related challenges, impose considerable physical and psychosocial burdens. Results will inform the development of patient resources aligned with patient priorities.


Subject(s)
Antibodies, Antiphospholipid , Antiphospholipid Syndrome , Qualitative Research , Humans , Female , Antiphospholipid Syndrome/psychology , Antiphospholipid Syndrome/immunology , Male , Antibodies, Antiphospholipid/immunology , Antibodies, Antiphospholipid/blood , Middle Aged , Adult , Canada , Quality of Life , Interviews as Topic , Lupus Erythematosus, Systemic/psychology , Lupus Erythematosus, Systemic/immunology , Pregnancy , Life Style
3.
Rheumatology (Oxford) ; 61(1): 24-41, 2021 12 24.
Article in English | MEDLINE | ID: mdl-34003972

ABSTRACT

OBJECTIVES: Cognitive dysfunction is common in patients with aPL (including primary APS or APS associated with SLE). Neuroimaging biomarkers may contribute to our understanding of mechanisms of cognitive dysfunction in these cohorts. This review aimed to investigate: (i) the prevalence of cognitive dysfunction in studies including neuroimaging biomarkers; and (ii) associations between cognition and neuroimaging biomarkers in patients with APS/aPL. METHODS: We conducted a systematic search of electronic databases PubMed, Science Direct, Scopus and PsycINFO, and included studies with descriptions of neuroimaging findings, cognitive dysfunction or both, in patients with aPL positivity (LA, IgG and IgM aCL and anti-ß2 glycoprotein-I antibodies). RESULTS: Of 120 search results we included 20 eligible studies (6 APS, 4 SLE with APS/aPL and 10 NPSLE). We identified a medium risk of bias in 6/11 (54%) of cohort studies and 44% of case-control studies, as well as marked heterogeneity in cognitive assessment batteries, APS and aPL definitions, and neuroimaging modalities and protocols. The prevalence of cognitive dysfunction ranged between 11 and 60.5%. Structural MRI was the most common imaging modality, reporting cognitive dysfunction to be associated with white matter hyperintensities, ischaemic lesions and cortical atrophy (four with cerebral atrophy, two with white matter hyperintensities and two with cerebral infarcts). CONCLUSION: Our findings confirm that cognitive impairment is commonly found in patients with aPL (including APS, SLE and NPSLE). The risk of bias, and heterogeneity in the cognitive and neuroimaging biomarkers reported does not allow for definitive conclusions.


Subject(s)
Antiphospholipid Syndrome/psychology , Cognitive Dysfunction/diagnostic imaging , Neuroimaging , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/diagnostic imaging , Biomarkers , Cognition , Cognitive Dysfunction/epidemiology , Cognitive Dysfunction/etiology , Dementia/epidemiology , Dementia/etiology , Humans , Prevalence
4.
Lupus ; 30(5): 707-714, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33509064

ABSTRACT

PURPOSE: Primary antiphospholipid syndrome (PAPS) is a chronic autoimmune disorder clinically characterized by thromboembolic events or obstetric complications. Prolonged anticoagulation therapy with vitamin K antagonists (VKA) is the treatment of choice for PAPS patients with thrombosis. However, the efficacy of VKA therapy depends on laboratory monitoring, dose adjustment, adequate lifestyle and adherence to treatment. Difficulties with VKA therapy can affect patients' self-perceived health related quality of life (HRQOL). This study aims to evaluate PAPS patients' HRQOL, therapy adherence and knowledge of treatment. METHODS: A general Medical Outcome Study Short Form-36 (SF-36) and the Duke Anticoagulation Satisfaction Scale (DASS) were used to access APS-patients self-perceived HRQOL. Treatment adherence was measured by the Treatment Measure Adhesion (TMA) - oral anticoagulant version instrument, and knowledge of VKA treatment was measured using the MedTake test. RESULTS: 66 PAPS patients using VKA were assessed. 63% of them were female; the mean age was 41.9 years old, approximately 60% had unprovoked venous thrombosis and one third of the patients had recurrent thrombotic events. The most impacted domain of DASS was "psychological impacts" and the factors associated to anticoagulation related poor HRQOL were: female sex, presence of arterial thrombosis and INR lability. Using the SF-36 instrument, PAPS-patients self-perceived HRQOL was poorer than that of the general Brazilian population and was associated with female sex and presence of cardiovascular risk factors. CONCLUSION: Despite the high adherence to treatment and knowledge of VKA therapy, self-perceived HRQOL is poor in patients with PAPS and is mainly affected by VKA therapy. Searching for better treatment options is warranted.


Subject(s)
Antiphospholipid Syndrome/drug therapy , Antiphospholipid Syndrome/psychology , Quality of Life/psychology , Self Concept , Vitamin K/antagonists & inhibitors , Administration, Oral , Adult , Anticoagulants/therapeutic use , Antiphospholipid Syndrome/complications , Brazil/epidemiology , Female , Heart Disease Risk Factors , Humans , Male , Middle Aged , Surveys and Questionnaires/standards , Thromboembolism/epidemiology , Thromboembolism/etiology , Thrombosis/etiology , Thrombosis/prevention & control , Treatment Adherence and Compliance/psychology
5.
Lupus ; 29(8): 924-933, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32501170

ABSTRACT

OBJECTIVE: This study aimed to explore the experience and impact of fatigue in adults with primary antiphospholipid syndrome (pAPS). METHODS: This sequential, explanatory mixed-methods study enrolled adults with a six-month or more history of pAPS. Consenting participants completed the Functional Assessment of Chronic Illness Therapy-Fatigue subscale (FS), Multi-Dimensional Perceived Social Support Scale, Patient Health Questionnaire (PHQ9), Pittsburgh Sleep Quality Index (PSQI), International Physical Activity Questionnaire (IPAQMETS). Relationships between FS and other variables were explored with multiple linear regression. Interviews were conducted with a subgroup of participants, and the data were analysed thematically. RESULTS: A total of 103 participants were recruited (Mage = 50.3 years; standard deviation = 10.1 years; 18 males). Of these, 62% reported severe fatigue. Greater fatigue was associated with lower mood, physical inactivity, poorer sleep quality and lower perceived social support. The best-fit model explained 56% of the variance in FS (adjusted R2 = 0.560, F(3, 74) = 33.65, p > 0.001) and included PHQ9 and IPAQMETS as significant predictors, and PSQI as a non-significant predictor. Twenty participants completed interviews. Three key themes were identified: characteristics of fatigue, impact on life and coping strategies. CONCLUSION: Fatigue was a common symptom of pAPS and challenging to manage. Other factors, particularly mood and physical activity, influenced fatigue. Evidence-based self-management interventions are needed.


Subject(s)
Antiphospholipid Syndrome/complications , Fatigue/physiopathology , Adaptation, Psychological , Adult , Antiphospholipid Syndrome/physiopathology , Antiphospholipid Syndrome/psychology , Cross-Sectional Studies , Exercise , Female , Humans , Linear Models , Male , Middle Aged , Multivariate Analysis , Surveys and Questionnaires
6.
Rheumatology (Oxford) ; 59(7): 1489-1494, 2020 Jul 01.
Article in English | MEDLINE | ID: mdl-32359070

ABSTRACT

The antiphospholipid antibody syndrome (APS), a chronic autoimmune thrombophilia with an increased mortality and morbidity, has been recognized for more than three decades. Unlike other autoimmune rheumatic conditions such as systemic lupus erythematosus, myositis and Sjögren's syndrome, relatively few attempts have been made to develop activity, damage or disease-specific quality of life indices for APS. In this review of the literature, we consider those attempts that have been made to develop assessment tools for patients with APS, but also reflect upon the nature of the condition, to discuss, in particular, whether an activity index is appropriate for this disease.


Subject(s)
Antiphospholipid Syndrome/physiopathology , Quality of Life , Thromboembolism/physiopathology , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/psychology , Humans , Outcome Assessment, Health Care , Thromboembolism/etiology
7.
Lupus ; 27(5): 837-840, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29301475

ABSTRACT

Objectives To detect the frequency of psychological alterations in primary antiphospholipid syndrome patients. Methods Thirty-six primary antiphospholipid syndrome patients were analyzed by a psychological interview using a standard protocol and review of medical charts. Clinical manifestations, associated comorbidities, antiphospholipid antibodies, and treatment were also evaluated. Results The mean age was 44.2 ± 10.8 years, 29 (80%) were women and 29 (80%) were of Caucasian race. The mean duration of disease was 7.3 ± 5.2 years. The frequency of the presence of psychological alterations was 97.1%. Family dependence was observed in 14 (40%), memory loss in 12 (34.3%), social losses in 12 (34.3%), sexual limitations in seven (20%), sadness in six (17.1%), severe speech limitation in four (11.4%), anxiety in three (8.6%), learning difficulty in two (5.7%), generalized phobia in two (5.7%), suicide ideation in one (2.6%), agoraphobia in one (2.6%), and obsessive-compulsive disorder in one (2.6%). Conclusion This study demonstrated that almost all primary antiphospholipid syndrome patients have psychological alterations. These data reinforce the need for psychological evaluation in primary antiphospholipid syndrome patients.


Subject(s)
Antiphospholipid Syndrome/complications , Mental Disorders/etiology , Adult , Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/psychology , Biomarkers/blood , Female , Humans , Male , Mental Disorders/diagnosis , Mental Disorders/psychology , Middle Aged , Preliminary Data , Risk Factors
8.
Mod Rheumatol ; 28(1): 147-155, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28463088

ABSTRACT

OBJECTIVE: Antiphospholipid (Hughes) syndrome (APS) is recognised as a systemic autoimmune disease defined by recurrent thromboembolic events and/or pregnancy morbidity. Little is known about the psychological burden of this long-term condition. This study aims to explore the relationship between social support and health-related quality of life (HRQoL) in patients with APS. METHODS: A total of 270 patients with a clinical diagnosis of APS participated in a cross-sectional online questionnaire survey. Data included demographics, disease-related information, social support and HRQoL. RESULTS: Both perceived and ideal social support were associated with HRQoL in APS. Patients reported receiving insufficient social support. Perceived emotional support was related to physical functioning (B = 7.77, p = .006, 95% CI: 2.25, 13.29); perceived instrumental support was associated with bodily pain (B = 17.52, p <  .001, 95% CI: 11.15, 23.90) and perceived informational support with physical and social functioning (B = -6.30, p = .05, 95% CI: -12.52, -0.08; B = 8.06, p = .02, 95% CI: 1.17, 14.94). Ideal emotional support was related to physical and social functioning (B = 5.80, p = .04, 95% CI: 0.26, 11.34; B = 7.53, p = .04, 95% CI: 0.55, 14.51); ideal instrumental support was associated with mental health (B = 4.73, p = .03, 95% CI: 0.38, 9.07) and ideal informational support with vitality (B = 5.85, p = .01, 95% CI: 1.23, 10.46). CONCLUSION: Social support was linked to HRQoL in patients with APS. Insufficient social support was associated with limitations in various HRQoL domains. Increasing social support especially through provision of disease-specific education might contribute to improving HRQoL in patients with APS. Patient-tailored interventions addressing psychosocial aspects of living with APS are needed to improve patients' psychological and physical status.


Subject(s)
Antiphospholipid Syndrome/psychology , Quality of Life/psychology , Social Support , Adolescent , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Health Status , Humans , Male , Middle Aged , Surveys and Questionnaires , Young Adult
9.
Int J Rheum Dis ; 20(6): 755-759, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28261992

ABSTRACT

AIM: To evaluate health-related quality of life (HRQoL) in primary antiphospholipid syndrome (PAPS) and correlate it with a crude estimate of accrual organ damage, comorbidity (diabetes mellitus, hypertension and dyslipidemia) and treatment (oral anticoagulation, immunosuppressors and prednisone). METHODS: We assessed HRQoL with the Short-Form 36 (SF-36) and the Lupus Quality of Life instrument (LupusQoL) and the disease burden with a modified Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR SDI). As controls we used SF-36 data from a Mexican general population within the same age range. RESULTS: We included 50 PAPS patients (86% women), mean age 47.6 ± 14.5 years, median disease duration 9.4 years, median SLICC/ACR score of 1 point and 80% had thrombotic events. PAPS patients had lower HRQoL than controls. We found a positive correlation between SF-36 and LupusQoL (r = 0.85, P < 0.0001). The SLICC/ACR SDI correlated negatively with both LupusQoL and SF-36, specifically the peripheral vascular domain (r = -0.29, P = 0.03, for both). Patients on oral anticoagulants (n = 37) had lower LupusQoL, physical functioning, intimate relationships, burden to others and pain scores as well as a lower SF-36 physical functioning score. We did not find differences in HRQoL regarding comorbidities and other treatments. CONCLUSIONS: HRQoL in PAPS was related to burden of the disease specifically at the vascular peripheral area and use of anticoagulants.


Subject(s)
Anticoagulants/administration & dosage , Antiphospholipid Syndrome/drug therapy , Blood Coagulation/drug effects , Quality of Life , Administration, Oral , Adult , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/psychology , Case-Control Studies , Comorbidity , Cost of Illness , Cross-Sectional Studies , Female , Glucocorticoids/administration & dosage , Humans , Immunosuppressive Agents/administration & dosage , Male , Mexico , Middle Aged , Prednisone/administration & dosage , Risk Factors , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome
10.
J Autoimmun ; 73: 92-9, 2016 09.
Article in English | MEDLINE | ID: mdl-27372915

ABSTRACT

OBJECTIVES: Antiphospholipid syndrome (APS) is associated with neurological manifestations and one of the novel autoantigens associated with this disease is Annexin A2 (ANXA2). In this work we have examined the effect of high levels of autoantibodies to ANXA2 on the brain in a mouse model. METHODS: Recombinant ANXA2 emulsified in adjuvant was used to immunize mice while mice immunized with adjuvant only served as controls. At peak antibody levels the animal underwent behavioral and cognitive tests and their brains were examined for ANXA2 immunoglobulin G (IgG) and expression of ANXA2 and the closely linked protein p11. RESULTS: Very high levels of anti-ANXA2 antibodies (Abs) were associated with reduced anxiety in the open field 13.14% ± 0.89% of the time in the center compared to 8.64% ± 0.91% observed in the control mice (p < 0.001 by t-test). A forced swim test found significantly less depression manifested by immobility in the ANXA2 group. The changes in behavior were accompanied by a significant reduction in serum corticosteroid levels of ANXA2 group compared to controls. Moreover, higher levels of total IgG and p11 expression were found in ANXA2 group brains. Lower levels of circulating anti-ANXA2 Abs were not associated with behavioral changes. CONCLUSIONS: We have established an animal model with high levels of anti-ANXA2 Abs which induced IgG accumulation in the brain and specific anxiolytic and anti-depressive effects. This model promises to further our understanding of autoimmune disease such as APS and to provide better understanding of the role of the ANXA2-p11 complex in the brain.


Subject(s)
Annexin A2/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/psychology , Anxiety/immunology , Autoantigens/immunology , Autoimmunity , Depression/immunology , Adjuvants, Immunologic/administration & dosage , Adrenal Cortex Hormones/blood , Animals , Annexin A2/metabolism , Anxiety/blood , Anxiety/pathology , Autoantibodies/analysis , Autoantibodies/immunology , Brain/pathology , Depression/blood , Depression/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/analysis , Immunoglobulin G/immunology , Mice , Mice, Inbred BALB C , Protein Multimerization , Psychological Tests , Recombinant Proteins/immunology , S100 Proteins/metabolism
11.
Lupus ; 24(11): 1161-8, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25862730

ABSTRACT

OBJECTIVES: Health-related quality of life (HRQoL) has not been fully explored in antiphospholipid syndrome (APS); therefore, we compared HRQoL between APS patients and the general population and assessed the impact of thromboembolic history. METHODS: HRQoL was measured in a multicentre cohort study by the Medical Outcomes Study Short-Form 36 (MOS-SF-36) questionnaire. HRQoL scores were compared to the French general population norms. Factors significantly associated with an impaired HRQoL were identified. RESULTS: A total of 115 patients with aPL and/or systemic lupus erythematosus (SLE) were included (mean age 42.7 ± 14.1 years old, 86 women). In 53 patients APS was diagnosed. Compared to general population norms, patients with APS had an impaired HRQoL. SLE-associated APS patients had the worst HRQoL scores (physical component summary (PCS)=40.8 ± 10.6; mental component summary (MCS)=40.6 ± 16.5) in comparison with SLE or aPL patients without thromboembolic history. In APS patients, history of arterial thrombosis significantly impaired HRQoL (PCS score: 42.2 ± 9.4 vs 49.2 ± 8.5; MCS score: 33.9 ± 13.7 vs 44.6 ± 10.3). CONCLUSION: Compared to the general population, APS patients experienced a lower HRQoL. In these patients, a history of arterial thrombosis significantly impaired HRQoL. Therefore, measurements of HRQoL should be included in APS patient management to assess the burden of the disease from a patient's perspective and to provide patients with the support they need.


Subject(s)
Antiphospholipid Syndrome/physiopathology , Adult , Antiphospholipid Syndrome/psychology , Cohort Studies , Female , Health Status , Humans , Lupus Erythematosus, Systemic/physiopathology , Lupus Erythematosus, Systemic/psychology , Male , Middle Aged , Outcome Assessment, Health Care , Quality of Life , Risk Factors , Surveys and Questionnaires , Thrombosis/physiopathology
12.
Rev Neurol ; 58(11): 500-4, 2014 Jun 01.
Article in Spanish | MEDLINE | ID: mdl-24861225

ABSTRACT

INTRODUCTION: Antiphospholipid syndrome (APS) is an autoimmune disorder which causes an hypercoagulation state characterized by thrombotic events, repetitive miscarriages and the presence of antiphospholipid antibodies. APS may be an isolated disease (primary APS) or associated to systemic lupus erythematous or another autoimmune conditions (secondary APS). Neuropsychiatric manifestations accompanying APS include migraine, epilepsy, chorea, dementia or psychosis. Detailed descriptions of clinical cases are lacking, and correlations between clinical and analytical findings are far from being well known. We review literature concerning neuropsychiatric manifestations in general and psychosis in particular, in patients suffering from AFS. CASE REPORT: A 23 years-old female who presented a primary AFS with a clinical debut consisting of neuropsychiatric manifestations characterized by psychosis (with two delusion episodes) and abnormal movements such as choreiform and hemiballistic movements, initially understood as conversive symptoms. CONCLUSIONS: We discuss the pathogenesis of the psychotic and motor manifestations. The etiology is nowadays not completely understood, but cerebral small vessel thrombosis might explain part of the manifestations. We also review the role of antipsychotic and antithrombotic medication for these patients. Currently, our patient remains asymptomatic without any antipsychotic agent, only being treated with antiagregant and antipalludic therapy.


TITLE: Psicosis como presentacion del sindrome antifosfolipido primario.Introduccion. El sindrome antifosfolipido (SAF) es un trastorno autoinmune que determina un estado de hipercoagulabilidad caracterizado por eventos tromboticos, abortos de repeticion y la presencia de anticuerpos antifosfolipido. Puede presentarse de manera aislada (SAF primario) o asociado a lupus eritematoso sistemico u otras enfermedades autoinmunes (SAF secundario). Las manifestaciones neuropsiquiatricas del SAF incluyen jaqueca, epilepsia, corea, demencia y psicosis. Se realiza una revision bibliografica de la sintomatologia neuropsiquiatrica en general y psicotica en particular de los pacientes afectos de SAF. Caso clinico. Mujer de 23 años afecta de un SAF primario que comenzo con manifestaciones clinicas unicamente neuropsiquiatricas consistentes en sintomatologia psicotica (dos episodios de clinica delirante) y movimientos anormales coreiformes y hemibalisticos que inicialmente se interpretaron como clinica conversiva. Conclusiones. Se discute la patogenesis de la sintomatologia motora y psicotica. La etiologia de los sintomas neuropsiquiatricos todavia no se conoce con claridad, pero la trombosis de pequeños vasos en el cerebro podria explicar parte de los sintomas. Asimismo, se revisa el papel que la medicacion antipsicotica y antitrombotica tiene para estos pacientes. En la actualidad, nuestra paciente se mantiene asintomatica sin necesidad de terapia antipsicotica y recibe tratamiento unicamente con un agente antiagregante y otro antipaludico.


Subject(s)
Antibodies, Anticardiolipin/blood , Antiphospholipid Syndrome/diagnosis , Chorea/etiology , Diagnostic Errors , Lupus Coagulation Inhibitor/blood , Psychotic Disorders/etiology , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/psychology , Brain/pathology , Chorea/physiopathology , Conversion Disorder/diagnosis , Delirium/etiology , Delirium/physiopathology , Dyskinesias/etiology , Dyskinesias/physiopathology , Female , Hallucinations/etiology , Hallucinations/physiopathology , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Intracranial Thrombosis/etiology , Intracranial Thrombosis/physiopathology , Neuroimaging , Psychotic Disorders/physiopathology , Young Adult
13.
Turk Psikiyatri Derg ; 24(4): 280-3, 2013.
Article in Turkish | MEDLINE | ID: mdl-24310096

ABSTRACT

Chorea gravidarum (CG) is a rare movement disorder characterized by rapid, irregular randomly distributed involuntary movements during pregnancy. Similar to Sydenham chorea, psychiatric symptoms may be observed in cases of CG. CG may be idiopathic or secondary to an underlying cause. One of the most common causes of CG is antiphospholipid syndrome. Herein we present a case of recurrent CG that was considered to be due to antiphospholipid syndrome. The patient had a history of 3 pregnancy losses and her fourth pregnancy was treated appropriately, resulting in the birth of healthy full-term baby. During the patient's first pregnancy CG was accompanied by psychotic symptoms and was misdiagnosed as conversion disorder.


Subject(s)
Antiphospholipid Syndrome/diagnosis , Chorea Gravidarum/diagnosis , Adult , Antiphospholipid Syndrome/psychology , Chorea Gravidarum/psychology , Conversion Disorder/diagnosis , Conversion Disorder/psychology , Diagnosis, Differential , Diagnostic Errors , Female , Humans , Infant, Newborn , Male , Pregnancy , Pregnancy Outcome , Prenatal Diagnosis , Psychiatric Status Rating Scales , Recurrence
14.
Psychosom Med ; 75(3): 326-30, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23533283

ABSTRACT

OBJECTIVE: This study aimed to improve understanding and treatment of psychiatric symptoms in antiphospholipid syndrome (APS) and to present an approach to the medical management of patients presenting with obsessive-compulsive disorder (OCD) with suspected neurovascular pathology. METHOD: A 15-year-old boy presented with severe OCD of recent onset. An infarct of the caudate nucleus was identified as the initial presentation of primary APS. This case report includes a selective literature review of the neuropsychiatric correlates of APS. RESULTS: The patient had OCD for 3 months with increasing symptoms resulting in admission for psychiatric reasons. After referral to the emergency department 3 weeks later, an infarct of the caudate nucleus was documented using magnetic resonance images of the brain, and APS was diagnosed based on additional laboratory findings. Anticoagulant treatment (enoxaparin and phenprocoumon) in this patient was effective in reducing obsessive-compulsive symptom severity. CONCLUSION: OCD may present as a neuropsychiatric manifestation of APS. The present observations are consistent with a thrombotic mechanism for neurologic or psychiatric symptoms in APS. In general, routine medical workup for childhood OCD is not indicated, but a comprehensive psychiatric, medical, and family history taking and physical examination are essential, particularly if OCD is of recent onset. The role of anticoagulant therapy in neuropsychiatric manifestations of APS without the presence of a cerebral infarct requires further research.


Subject(s)
Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/psychology , Obsessive-Compulsive Disorder/complications , Obsessive-Compulsive Disorder/psychology , Adolescent , Anticoagulants/therapeutic use , Antiphospholipid Syndrome/drug therapy , Caudate Nucleus/pathology , Diagnosis, Differential , Enoxaparin/therapeutic use , Humans , Magnetic Resonance Imaging/methods , Male , Phenprocoumon/therapeutic use , Psychiatric Status Rating Scales , Severity of Illness Index , Treatment Outcome
15.
Curr Opin Obstet Gynecol ; 24(4): 229-34, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22729089

ABSTRACT

PURPOSE OF REVIEW: Acquired and inherited thrombophilia is an important research avenue in the recurrent miscarriage field. The optimum treatment for patients with recurrent miscarriage and a confirmed thrombophilia remains a contentious issue. We aim to appraise and explore the latest research in the field of thrombophilia and recurrent miscarriage in this review. RECENT FINDINGS: Antiphospholipid syndrome (APS) is the only proven thrombophilia that is associated with adverse pregnancy outcomes. Research involving inherited thrombophilia and recurrent miscarriage is limited to small observational studies with small and heterogeneous populations. Aspirin and heparin therapy are frequently prescribed for APS, yet there is no robust evidence for the most efficacious regime. The combination of inherited hypercoagulability and environmental factors in association with recurrent miscarriage has recently been explored as an aid to identify high-risk individuals. SUMMARY: The cause of recurrent miscarriage is multifactorial and appropriate treatment continues to be a challenge. Laboratory tests need to be standardized and well designed multicentre research trials are essential to expand on the current knowledge base with the aim to produce strong evidence-based medicine.


Subject(s)
Abortion, Habitual/etiology , Anticoagulants/therapeutic use , Antiphospholipid Syndrome/complications , Pregnancy Complications, Hematologic/etiology , Thrombophilia/complications , Abortion, Habitual/prevention & control , Abortion, Habitual/psychology , Antiphospholipid Syndrome/drug therapy , Antiphospholipid Syndrome/psychology , Aspirin/therapeutic use , Evidence-Based Medicine , Female , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Pregnancy , Pregnancy Complications, Hematologic/drug therapy , Pregnancy Complications, Hematologic/psychology , Pregnancy, High-Risk , Thrombophilia/drug therapy , Thrombophilia/psychology
16.
J Geriatr Psychiatry Neurol ; 25(1): 26-8, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22467843

ABSTRACT

Antiphospholipidsyndrome (APS) is an autoimmune disorder which causes a hyper-coagulable state characterized by recurrent thrombosis. It has a diverse range of central nervous system manifestations. We describe a case of a 61 year old man with bipolar disorder and APS, and we compare this to a previously reported case. Additionally, we reviewed literature regarding APS-related markers and the relationship of APS to other psychiatric and neurologic illnesses. We discuss possible mechanisms for an association between APS and bipolar disorder. We encourage clinicians to be aware of this possible relationship and have proposed research strategies.


Subject(s)
Antiphospholipid Syndrome/complications , Bipolar Disorder/complications , Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/psychology , Humans , Male , Middle Aged , Thrombosis/complications
17.
Gen Hosp Psychiatry ; 34(5): 579.e1-3, 2012.
Article in English | MEDLINE | ID: mdl-22460000

ABSTRACT

OBJECTIVE: Neuropsychiatric symptoms may be the main manifestations and very early symptoms of developing autoimmune diseases. Early detection and treatment could reverse psychotic symptoms and restore cognitive function. CASE REPORT: A 24-year-old woman presented with acute psychotic symptoms. Routine physical examinations revealed only mild fever. Due to positive antiphospholipid antibodies, low protein S with elevated d-dimer and brain hypoperfusion, early-phase antiphospholipid syndrome (APS) was suspected. Early immunomodulation treatment led to complete remission of the psychotic symptoms, preservation of cognitive function and prevention of APS progression. CONCLUSION: Since early detection and treatment can reverse the progression of autoimmune diseases with central nervous system involvement, these should be highlighted when managing high-risk patients.


Subject(s)
Antiphospholipid Syndrome/psychology , Paranoid Disorders/psychology , Early Diagnosis , Female , Humans , Taiwan , Young Adult
18.
Clin Rheumatol ; 31(3): 403-6, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22218779

ABSTRACT

Although antiphospholipid syndrome (APS) is a multisystem prothrombotic condition, its inflammatory nature has been increasingly recognized in recent years. Stroke and transitory ischemic attacks are the neurological manifestations included in APS criteria, however many other neurological involvements have been attributed to antiphospholipid antibodies (aPL), such as seizures, transverse myelitis, and cognitive impairment. In this article we will review evidence from animal model that explain the role of aPL in cognition.


Subject(s)
Antiphospholipid Syndrome/complications , Cognition Disorders/complications , Animals , Antiphospholipid Syndrome/psychology , Cognition Disorders/psychology , Disease Models, Animal , Humans
19.
Rheumatology (Oxford) ; 51(1): 157-68, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22075066

ABSTRACT

OBJECTIVE: To analyse risk factors and comorbidities potentially associated with CNS involvement in a large cohort of Italian patients affected by SLE. METHODS: A number of generic (not strictly SLE related) and specific (disease related) risk factors to which all patients have been exposed in the span of 5 years before the first neuropsychiatric (NP) event or before the last available observation were checked for and their distribution was analysed in 959 SLE patients with and without NP involvement; all the first NP events that occurred in a time frame of 10 years were recorded and categorized as SLE related or SLE unrelated. RESULTS: Three hundred and twenty-six SLE patients with and 633 SLE patients without NP manifestations were included in the study. A total of 469 NP events were recorded. Headache (26.1%), cerebrovascular events (22.7%), mood disorders (8.9%), seizures (14.4%) and cognitive dysfunctions (9.5%) were the most frequent SLE-related NP events. More risk factors [mean 4.52 (2.44) vs 3.73 (2.01); P < 0.0001] were observed in patients with than without NP involvement. Overall, aPLs, LA and APS were factors more strongly associated with NP involvement. CONCLUSIONS: In SLE, NP involvement and aPLs were confirmed as closely related. Furthermore, other modifiable generic risk factors, such as hypertension, carotid vasculopathy and dyslipidaemia, appeared to be related to the occurrence of cerebral vascular accident (CVA) and cognitive dysfunctions, suggesting the need for a more intensive preventive strategy to optimize the management of NP lupus.


Subject(s)
Lupus Vasculitis, Central Nervous System/psychology , Mental Disorders/etiology , Adult , Antibodies, Antiphospholipid/blood , Antiphospholipid Syndrome/epidemiology , Antiphospholipid Syndrome/psychology , Biomarkers/blood , Comorbidity , Epidemiologic Methods , Female , Headache Disorders/epidemiology , Headache Disorders/etiology , Humans , Italy/epidemiology , Lupus Vasculitis, Central Nervous System/complications , Lupus Vasculitis, Central Nervous System/epidemiology , Male , Mental Disorders/epidemiology , Middle Aged , Prognosis , Stroke/epidemiology , Stroke/etiology
20.
Lupus ; 20(13): 1433-5, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21768180

ABSTRACT

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by recurrent thrombotic events, miscarriages and thrombocytopenia with persistently positive antiphospholipid antibodies.( 1,2 ) APS may be isolated (primary APS) or associated to a connective tissue disease, most often systemic lupus erythematosus (SLE).( 1,2 ) APS usually affects young patients before the fifth decade( 3 ) with stroke being the commonest neurological manifestation.( 4 ) Various other neurological manifestations are being recognized in patients with APS including migraine, epilepsy, multi-infarct dementia and chorea.( 2 ) The pathological process underlying the neurological manifestations remains obscure.( 1,2 ) Herein we report a case of primary APS presenting with a group of unusual neurological manifestations in a 68-year-old woman.


Subject(s)
Antiphospholipid Syndrome/complications , Encephalitis/etiology , Psychotic Disorders/etiology , Seizures/etiology , Aged , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/pathology , Antiphospholipid Syndrome/psychology , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL